Annual Report

The report describes Implantica's 2025 progress toward establishing RefluxStop® as a new standard of care, including major FDA PMA milestones and launch preparation. It highlights positive NICE guidance in the UK and real-world safety evidence from 602 patients across 22 European centers. The report also presents sustainability, innovation, and human capital as contributors to long-term value creation.